Core Viewpoint - The "Annual Excellence Innovation IPO" award was presented to Silver诺医药-B (02591.HK) during the "Technology Empowerment · Capital Breakthrough" online sharing session held by 格隆汇 on December 22, recognizing the company's achievements in product, model, and organizational innovation over the past year [1] Group 1 - The award aims to honor newly listed companies that have achieved excellent results through continuous innovation in response to market trends [1]

Core Viewpoint - The "Annual Excellence in Innovation IPO" award recognizes companies that have demonstrated significant achievements in product, model, and organizational innovation over the past year, highlighting their ability to keep pace with market trends through continuous innovation [4]. Group 1: Award Recipients - Six companies were awarded the "Annual Excellence in Innovation IPO" award: MIRXES-B (02629.HK), Wuyi Vision (06651.HK), Yino Pharma (02591.HK), Yunhan Chip City (301563.SZ), Yunjing (02670.HK), and Yunzhisheng (09678.HK) [1]. - The ranking of the awarded companies is not in any specific order and is based on the first letter of their names [1]. Group 2: Evaluation Criteria - The evaluation for the award was based on quantitative data analysis and assessments from an expert review panel [4]. - The award aims to create a valuable reference list of listed companies and unicorns within the investment community, covering all companies listed on major exchanges including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [4].

Core Viewpoint - The "Golden Award" annual excellence company selection by Gelonghui recognizes innovative companies in the IPO sector, highlighting their achievements in product, model, and organizational innovation over the past year [1][2]. Group 1: Award Winners - Six companies received the "Annual Excellence Innovation IPO" award: MIRXES-B (02629.HK), Wuyi Vision (06651.HK), Yinnuo Pharmaceutical-B (02591.HK), Yunhan Chip City (301563.SZ), Yunjin (02670.HK), and Yunzhisheng (09678.HK) [1]. - The ranking of the award winners is not in any particular order and is based on the first letter of the company names [1]. Group 2: Evaluation Criteria - The award evaluates companies based on quantitative data analysis and expert review, focusing on their innovation in products, business models, and organizational structures [1]. - The aim of the selection is to recognize new listed companies that have achieved excellent results through continuous innovation and alignment with market trends [1]. Group 3: Scope of the Selection - The "Golden Award" selection covers all listed companies and unicorns on major stock exchanges, including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [2]. - The initiative is driven by the vision of providing valuable references for investors regarding listed companies and unicorns in the market [2].

廣州銀諾醫藥集團股份有限公司 章程 （H股發行後適用） 1 | 第一章 | 總則 | 4 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 5 | | 第三章 | 股份 | 6 | | 第一節 | 股份發行 | 6 | | 第二節 | 股份增減和回購 | 10 | | 第三節 | 股份轉讓 | 11 | | 第四章 | 股東和股東會 | 12 | | 第一節 | 股東 | 12 | | 第二節 | 股東會的一般規定 | 18 | | 第三節 | 股東會的召集 | 21 | | 第四節 | 股東會的提案與通知 | 23 | | 第五節 | 股東會的召開 | 25 | | 第六節 | 股東會的表決和決議 | 29 | | 第五章 | 董事會 | 34 | | 第一節 | 董事 | 34 | | 第二節 | 董事會 | 38 | | 第六章 | 總經理及其他高級管理人員 | 43 | | 第七章 | 監事會 | 45 | | --- | --- | --- | | 第一節 | 監事 | 45 | | 第二節 | 監事會 | 45 | | 第八章 | 財務會計制度、利潤分配和審計 | 4 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Guangzhou Innogen Pharmaceutical Group Co., Ltd. 廣州銀諾醫藥集團股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2591） 章程修訂 本公告乃廣州銀諾醫藥集團股份有限公司（「本公司」）根據香港聯合交易所有限公 司（「聯交所」）證券上市規則第13.51(1)條刊發。 H股於2025年8月15日在聯交所主板完成發行上市（「上市」）後，為反映本公司上 市後註冊資本、股份總數等情況的相關變動，本公司須修訂其章程（「章程」）並辦 理完成有關章程變更的備案。 於本公告日期，董事會包括執行董事WANG QINGHUA博士、姜帆女士、徐文潔 女士及黃冰先生；非執行董事HO KYUNG SHIK先生及衡磊先生；及獨立非執行 董事陶武平先生、宋瑞霖博士及陳向榮先生。 根據本公司於2024年10月30日的臨時股東會會議通過的決議案，董事會及董事 會授權人員已獲 ...

Core Viewpoint - The stock of Innovent Biologics-B (02591) rose over 3%, reaching HKD 32, following the announcement that its innovative drug, Icosapent Ethyl (brand name: Yinuo Qing®), has been included in the 2025 National Medical Insurance Drug List in China, marking a significant step towards making diabetes treatment more accessible [1]. Group 1: Company Developments - Innovent Biologics' Icosapent Ethyl is the first long-acting human GLP-1 receptor agonist (GLP-1RA) developed in China, aimed at controlling blood sugar levels in adult patients with type 2 diabetes [1]. - The drug will officially be implemented in the national insurance scheme starting January 1, 2026, enhancing its market accessibility [1]. Group 2: Industry Impact - The inclusion of Icosapent Ethyl in the national insurance list aligns with the "Healthy China 2030" initiative, which aims to advance diabetes prevention and treatment [1]. - The National Guidelines for Diabetes Prevention and Management (2025) classify Icosapent Ethyl as a GLP-1RA injectable medication, providing a policy framework for its use in primary healthcare settings [1]. - The guidelines highlight GLP-1RA as a crucial treatment option for adult type 2 diabetes patients with comorbidities such as atherosclerotic cardiovascular disease (ASCVD), heart failure, chronic kidney disease (CKD), and those needing weight management [1].

Core Insights - The stock price of Sinocare Inc. (02591) increased by 5.37%, currently trading at HKD 32.60, with a transaction volume of HKD 33.25 million [1][4] - The first domestically developed ultra-long-acting human GLP-1 receptor agonist, Icosapent Ethyl (brand name: Yinuo Qing®), has been officially included in the 2025 National Medical Insurance Drug List, effective from January 1, 2026, aimed at controlling blood sugar in adult patients with type 2 diabetes [1][4] - This inclusion marks a significant step towards the accessibility of innovative diabetes treatments in China, aligning with the "Healthy China 2030" initiative [1][4] Industry Developments - The National Guidelines for Diabetes Prevention and Control (2025) have classified Icosapent Ethyl as a GLP-1 receptor agonist injectable, providing direct policy and regulatory support for its use in primary healthcare institutions [1][4] - The guidelines emphasize the importance of GLP-1 receptor agonists as a treatment option for adult type 2 diabetes patients with comorbidities such as atherosclerotic cardiovascular disease (ASCVD), heart failure, chronic kidney disease (CKD), and those requiring weight management [1][4]

Group 1 - The stock of Sino Biopharmaceutical Limited (02591.HK) increased by over 3% during trading, reaching a rise of 3.43% at HKD 32 per share [1] - The trading volume amounted to HKD 20.7421 million [1]

Core Viewpoint - The inclusion of the innovative long-acting human GLP-1 receptor agonist, Icosapent Ethyl (brand name: Yinuo Qing), in the 2025 National Medical Insurance Drug List marks a significant step towards making diabetes treatment more accessible in China, aligning with the "Healthy China 2030" initiative [1] Group 1: Company Developments - Yinuo Pharmaceutical-B (02591) saw its stock price increase by 3.43%, reaching HKD 32, with a trading volume of HKD 20.74 million [1] - The company’s product, Icosapent Ethyl, is now recognized as the first domestically developed long-acting GLP-1 receptor agonist in China [1] Group 2: Industry Impact - The inclusion of Icosapent Ethyl in the national insurance list is aimed at improving the accessibility of innovative diabetes medications [1] - The 2025 National Guidelines for Diabetes Prevention and Management highlight Icosapent Ethyl as a key treatment option for adult patients with type 2 diabetes, especially those with cardiovascular disease risk factors, heart failure, chronic kidney disease, and obesity [1]

Core Viewpoint - The inclusion of the innovative long-acting human GLP-1 receptor agonist, Icosapent Ethyl (brand name: Yinuo Qing), in the 2025 National Medical Insurance Drug List marks a significant step towards making diabetes treatment more accessible in China, aligning with the "Healthy China 2030" initiative [1] Group 1: Company Developments - Silver诺医药-B (02591) saw its stock price increase by 3.43%, reaching HKD 32, with a trading volume of HKD 20.74 million [1] - The company’s drug, Icosapent Ethyl, is now officially recognized for the treatment of blood sugar control in adult patients with type 2 diabetes, effective from January 1, 2026 [1] Group 2: Industry Impact - The inclusion of Icosapent Ethyl in the National Medical Insurance Drug List is a crucial advancement for the accessibility of innovative diabetes treatments in China [1] - The "National Guidelines for Diabetes Prevention and Management (2025)" lists Icosapent Ethyl as a key injectable GLP-1RA, providing policy and regulatory support for its use in primary healthcare settings [1] - The guidelines emphasize the importance of GLP-1RA for adult type 2 diabetes patients with comorbidities such as atherosclerotic cardiovascular disease (ASCVD), heart failure, chronic kidney disease (CKD), and those needing weight management [1]